SciELO - Scientific Electronic Library Online

 
vol.48 número2The expression and modulation of CEACAM1 and tumor cell transformationQuality of life, vulnerability and resilience: a qualitative study of the tsunami impact on the affected population of Sri Lanka índice de autoresíndice de assuntospesquisa de artigos
Home Page  

Serviços Personalizados

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Annali dell'Istituto Superiore di Sanità

versão impressa ISSN 0021-2571

Resumo

INCORVAIA, Cristoforo et al. Treating allergic rhinitis by sublingual immunotherapy: a review. Ann. Ist. Super. Sanità [online]. 2012, vol.48, n.2, pp. 172-176. ISSN 0021-2571.  http://dx.doi.org/10.4415/ANN_12_02_10.

OBJECTIVE: Allergic rhinitis (AR) is a disease with high and increasing prevalence. The management of AR includes allergen avoidance, anti-allergic drugs, and allergen specific immunotherapy (AIT), but only the latter works on the causes of allergy and, due to its mechanisms of action, modifies the natural history of the disease. Sublingual immunotherapy (SLIT) was proposed in the 1990s as an option to traditional, subcutaneous immunotherapy. MATERIAL AND METHODS: We reviewed all the available controlled trials on the efficacy and safety of SLIT. RESULTS AND CONCLUSION: Thus far, more than 60 trials, globally evaluated in 6 meta-analyses, showed that SLIT is an effective and safe treatment for AR. However, it must be noted that to expect clinical efficacy in the current practice SLIT has to be performed following the indications from controlled trials, that is, sufficiently high doses to be regularly administered for at least 3 consecutive years.

Palavras-chave : allergic rhinitis; sublingual immunotherapy; efficacy; safety; compliance; meta-analysis.

        · resumo em Italiano     · texto em Inglês     · pdf em Inglês